MIRD Pamphlet No. 22 (abridged): Radiobiology and Dosimetry of Alpha-particle Emitters for Targeted Radionuclide Therapy

Overview

Journal J Nucl Med

Specialty Nuclear Medicine

Date 2010 Jan 19

PMID 20080889

Citations 207

Authors

John C Roeske

Michael R McDevitt

Stig Palm

Barry J Allen

Hong Song

Gamal Akabani

Wesley E Bolch

A Bertrand Brill

Darrell R Fisher

Roger W Howell

Ruby F Meredith

George Sgouros

Barry W Wessels

Pat B Zanzonico

Affiliations

Soon will be listed here.

Abstract

The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.

Citing Articles

Mathematic Modeling of Tumor Growth During [Lu]Lu-PSMA Therapy: Insights into Treatment Optimization.

Zaid N, Bastiaannet R, Hobbs R, Sgouros G J Nucl Med. 2025; 66(1):84-90.

PMID: 39753362 PMC: 11705791. DOI: 10.2967/jnumed.124.268457.

Fractionated alpha and mixed beam radiation promote stronger pro-inflammatory effects compared to acute exposure and trigger phagocytosis.

Karimi Roshan M, Belikov S, Ix M, Protti N, Balducci C, Dodel R Front Cell Neurosci. 2024; 18:1440559.

PMID: 39717389 PMC: 11663654. DOI: 10.3389/fncel.2024.1440559.

Preclinical Comparison of [In]In- and [Ac]Ac-DOTA-Trastuzumab IgG, F(ab') and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer.

Kondo M, Cai Z, Chan C, Brown M, Reilly R Mol Pharm. 2024; 22(1):474-487.

PMID: 39666273 PMC: 11708818. DOI: 10.1021/acs.molpharmaceut.4c01071.

Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.

Hong J, Bae S, Cavinato L, Seifert R, Ryhiner M, Rominger A Theranostics. 2024; 14(18):7122-7139.

PMID: 39629134 PMC: 11610134. DOI: 10.7150/thno.99516.

Optimization Processes of Clinical Chelation-Based Radiopharmaceuticals for Pathway-Directed Targeted Radionuclide Therapy in Oncology.

Tomiyoshi K, Wilson L, Mourtada F, Mourtada J, Namiki Y, Kamata W Pharmaceutics. 2024; 16(11).

PMID: 39598580 PMC: 11597032. DOI: 10.3390/pharmaceutics16111458.

References

MUNRO T . The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res. 1970; 42(3):451-70. View

Goddu S, Howell R, Rao D . Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med. 1994; 35(2):303-16. View

THOMLINSON R, GRAY L . The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9(4):539-49. PMC: 2073776. DOI: 10.1038/bjc.1955.55. View

Macklis R, Kinsey B, Kassis A, Ferrara J, Atcher R, HINES J . Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988; 240(4855):1024-6. DOI: 10.1126/science.2897133. View

Miederer M, McDevitt M, Sgouros G, Kramer K, Cheung N, Scheinberg D . Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004; 45(1):129-37. View

Sgouros G, Song H . Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis. Cancer Biother Radiopharm. 2008; 23(1):74-81. PMC: 2977973. DOI: 10.1089/cbr.2007.0408. View

Rao D, Narra V, Howell R, Govelitz G, Sastry K . In-vivo radiotoxicity of DNA-incorporated 125I compared with that of densely ionising alpha-particles. Lancet. 1989; 2(8664):650-3. PMC: 8172252. DOI: 10.1016/s0140-6736(89)90896-9. View

Narra V, Harapanhalli R, Howell R, Sastry K, Rao D . Vitamins as radioprotectors in vivo. I. Protection by vitamin C against internal radionuclides in mouse testes: implications to the mechanism of damage caused by the Auger effect. Radiat Res. 1994; 137(3):394-9. View

. ICRP Publication 105. Radiation protection in medicine. Ann ICRP. 2008; 37(6):1-63. DOI: 10.1016/j.icrp.2008.08.001. View

10.

Sgouros G, Ballangrud A, Jurcic J, McDevitt M, Humm J, Erdi Y . Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. J Nucl Med. 1999; 40(11):1935-46. View

11.

Narra V, Harapanhalli R, Goddu S, Howell R, Rao D . Radioprotection against biological effects of internal radionuclides in vivo by S-(2-aminoethyl)isothiouronium bromide hydrobromide (AET). J Nucl Med. 1995; 36(2):259-66. View

12.

Cox R, Masson W . Mutation and inactivation of cultured mammalian cells exposed to beams of accelerated heavy ions. III. Human diploid fibroblasts. Int J Radiat Biol Relat Stud Phys Chem Med. 1979; 36(2):149-60. DOI: 10.1080/09553007914550901. View

13.

Kneifel S, Cordier D, Good S, Ionescu M, Ghaffari A, Hofer S . Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006; 12(12):3843-50. DOI: 10.1158/1078-0432.CCR-05-2820. View

14.

Bruland O, Nilsson S, Fisher D, Larsen R . High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?. Clin Cancer Res. 2006; 12(20 Pt 2):6250s-6257s. DOI: 10.1158/1078-0432.CCR-06-0841. View

15.

Geerlings M, Kaspersen F, Apostolidis C, van der Hout R . The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy. Nucl Med Commun. 1993; 14(2):121-5. DOI: 10.1097/00006231-199302000-00009. View

16.

McDevitt M, Ma D, Lai L, Simon J, Borchardt P, Frank R . Tumor therapy with targeted atomic nanogenerators. Science. 2001; 294(5546):1537-40. DOI: 10.1126/science.1064126. View

17.

Siegel J, Thomas S, STUBBS J, Stabin M, Hays M, Koral K . MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999; 40(2):37S-61S. View

18.

Goddu S, Narra V, Harapanhalli R, Howell R, Rao D . Radioprotection by DMSO against the biological effects of incorporated radionuclides in vivo--Comparison with other radioprotectors and evidence for indirect action of Auger electrons. Acta Oncol. 1996; 35(7):901-7. DOI: 10.3109/02841869609104044. View

19.

Palm S, Humm J, Rundqvist R, Jacobsson L . Microdosimetry of astatine-211 single-cell irradiation: role of daughter polonium-211 diffusion. Med Phys. 2004; 31(2):218-25. DOI: 10.1118/1.1640951. View

20.

Howell R, Goddu S, Narra V, Fisher D, Schenter R, Rao D . Radiotoxicity of gadolinium-148 and radium-223 in mouse testes: relative biological effectiveness of alpha-particle emitters in vivo. Radiat Res. 1997; 147(3):342-8. PMC: 3321061. View